SHH and neoplasm: Based on data from a genetically engineered mouse model (GEMM), Shh pathway inhibitor (IPI‐926) treatment yielded reduced tumor–stroma and increased survival compared to controls, while also increasing tumor vascularity and gemcitabine delivery.